XIDX
SDPC
Market cap10mUSD
Nov 12, Last price
142.00IDR
Name
Millennium Pharmacon International Tbk PT
Chart & Performance
P/E
10.70
P/S
0.05
EPS
13.28
Div Yield, %
1.76%
Shrs. gr., 5y
—
Rev. gr., 5y
7.51%
Revenues
3.92t
+16.45%
Net income
16.91b
-48.88%
CFO
-125.45b
L+36.88%
Dividend
Jun 11, 20242.5 IDR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Millennium Pharmacon International Tbk engages in the distribution and trading of prescription and non-prescription medicines, dietary supplements, and medical devices in Indonesia. The company distributes its products through drug stores, pharmacies, hospitals, supermarkets, and retail shops. As of December 31, 2021, it operated 33 branch offices in Java, Bali, Sumatera, Kalimantan, and Sulawesi Islands. The company was formerly known as PT NVPD Soedarpo Corporation Tbk and changed its name to PT Millennium Pharmacon International Tbk in February 1990. The company was founded in 1952 and is headquartered in Jakarta Selatan, Indonesia. PT Millennium Pharmacon International Tbk is a subsidiary of Pharmaniaga International Corporation Sdn. Bhd.
IPO date
May 07, 1990
Employees
Domiciled in
ID
Incorporated in
ID
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||